テキサスにおけるバーキットリンパ腫の臨床試験
テキサス内の拠点で、バーキットリンパ腫に関する24件の研究が参加者を募集しています。
テキサス内の都市
- Houston21件の研究
- Dallas7件の研究
- San Antonio7件の研究
- Austin5件の研究
- Corpus Christi4件の研究
- El Paso4件の研究
- Fort Worth4件の研究
- Lubbock3件の研究
- Killeen3件の研究
公式研究テキスト（英語）
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- 他10件
被験者募集中第2相
366 Days – 46 Years · 全性別 · 2026/10/02更新 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Houston Methodist Hospital, Houston
被験者募集中第3相
18歳〜39歳 · 全性別 · 2026/10/02更新 · NCT03150693Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
被験者募集中観察研究
0歳〜38歳 · 全性別 · 2026/10/01更新 · NCT06131801Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- 他7件
被験者募集中第2相
365 Days · 全性別 · 2026/09/25更新 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Baylor College Medical Center (Data Collection Only), Houston
- Texas Children's Hospital (Data Collection), Houston
被験者募集中第3相
1歳以上 · 全性別 · 2026/09/17更新 · NCT07223021Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
被験者募集中第1/2相
6 Months – 25 Years · 全性別 · 2026/09/17更新 · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Methodist Children's Hospital, San Antonio
被験者募集中第1相
0歳〜18歳 · 全性別 · 2026/09/16更新 · NCT06173518Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Baylor University Medical Center, Dallas
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/08更新 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- 他10件
被験者募集中第2相
1歳〜30歳 · 全性別 · 2026/09/01更新 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- 他12件
被験者募集中第3相
365 Days – 25 Years · 全性別 · 2026/08/25更新 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- University of Texas, Southwestern, Dallas
- Baylor Texas Children's Hospital, Houston
被験者募集中第2相
7歳〜25歳 · 全性別 · 2026/08/19更新 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Houston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/08/19更新 · NCT06137118Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
- MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06287229Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- M D Anderson Cancer Center, Houston
被験者募集中第2相
15歳以上 · 全性別 · 2026/08/10更新 · NCT03136146Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- M D Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/15更新 · NCT01371630Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Houston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/07/13更新 · NCT07109219Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
- M D Anderson Cancer Center, Houston
被験者募集中第2相
14歳以上 · 全性別 · 2026/05/20更新 · NCT02877303Study of SGR-1505 in Mature B-Cell Neoplasms
- University of Texas Southwestern, Dallas
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT05544019Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2025/11/05更新 · NCT04260022Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Sarah Cannon - St. David's South Austin Medical Center, Austin
- MD Anderson Cancer Center, Houston
- Sarah Cannon - Texas Transplant Institute at Methodist Hospital, San Antonio
被験者募集中第1/2相
15歳〜50歳 · 全性別 · 2025/09/09更新 · NCT04150497The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- The University of Texas M. D. Anderson Cancer Center, Houston
- Methodist Healthcare System, San Antonio
被験者募集中第2相
1歳〜25歳 · 全性別 · 2025/05/04更新 · NCT03509961Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2024/11/15更新 · NCT06034275ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。